Press Releases

Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies

LEXINGTON, Mass., Jan. 6, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that it has entered into a research collaboration with Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery.  The collaboration will leverage Pulmatrix's iSPERSE™ platform and expertise in seeking to transform promising assets to improve drug delivery and safety profiles.

Pulmatrix logo (PRNewsFoto/Pulmatrix, Inc.)

"This collaboration is an important milestone validating the promise of the iSPERSE™ platform for research and partnering capabilities," said Ted Raad, Chief Executive Officer of Pulmatrix. "At Pulmatrix, we have successfully applied our technology to improve the delivery of a diverse range of inhaled molecules and believe our approach has the potential to broadly benefit the development and reach of inhaled therapeutics. We are thrilled to enter this collaboration with Nocion and look forward to applying our innovative technology and know how to help them accomplish their goal of advancing promising new candidates that revolutionize the treatment of conditions arising from neurogenic inflammation."

Richard P. Batycky, Ph.D., Chief Executive Officer of Nocion Therapeutics, said "We are excited to be working with Pulmatrix to evaluate the formulatability of our respiratory compounds.  The combination of their experienced team, their skill with standard dry powder techniques and their proprietary iSPERSE™ platform will allow for a thorough evaluation of our compounds to help advance our promising drug candidates." Dr. Batycky also serves on the Board of Directors of Pulmatrix.

About Pulmatrix          

Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.

About Nocion

Nocion Therapeutics is a biopharmaceutical company developing novel small molecule charged sodium channel blockers, "nocions", that selectively affect actively firing nociceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions involving cough, itch, and pain. The company's mission is to safely alleviate suffering for millions of patients with conditions arising from activated sensory neurons. For more information, visit:


Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as "anticipates," "assumes," "believes," "can," "could," "estimates," "expects," "forecasts," "guides," "intends," "is confident that", "may," "plans," "seeks," "projects," "targets," and "would," and their opposites and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the SEC, including its annual report on Form 10-K filed with the Securities and Exchange Commission on February 19, 2019, as amended on July 24, 2019, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact                                              
Timothy McCarthy, CFA

SOURCE Pulmatrix, Inc.